组学时代的线粒体医学
线粒体疾病是最常见且严重的遗传性遗传病之一,具有临床、生化和遗传异质性,诊断历程漫长且缺乏疾病修饰性治愈疗法。本文综述高通量组学技术推动的线粒体生物学与医学进展,并讨论线粒体疾病的新兴疗法。
要点
- 线粒体维护需两个基因组编码的约1500种蛋白,任一基因组突变可破坏细胞代谢与稳态。
- 组学技术加速原发性线粒体病的遗传诊断,并揭示新病理机制与治疗靶点。
- 线粒体疾病仍缺乏疾病修饰性治愈疗法,诊断历程漫长。
核心结论
- 组学技术将持续揭示线粒体未解问题,为改善线粒体疾病患者结局铺路。
研究设计与样本
- 本文为综述,讨论高通量组学技术广泛使用带来的线粒体生物学与医学进展。
主要发现
- 对线粒体生物能量与生物合成功能的新认识加速了原发性线粒体病的遗传诊断。
- 组学技术识别了新的线粒体病理机制和治疗干预新靶点。
关键数值与推荐
- 线粒体维护需要来自两个基因组的约1500种蛋白。
临床怎么用
- 临床可借助组学技术加速原发性线粒体病的遗传诊断并识别新的治疗靶点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Mitochondria are dynamic bioenergetic organelles whose maintenance requires around 1500 proteins from two genomes. Mutations in either the mitochondrial or nuclear genome can disrupt a plethora of cellular metabolic and homoeostatic functions. Mitochondrial diseases represent one of the most common and severe groups of inherited genetic disorders, characterised by clinical, biochemical, and genetic heterogeneity, diagnostic odysseys, and absence of disease-modifying curative therapies. This Review aims to discuss recent advances in mitochondrial biology and medicine arising from widespread use of high-throughput omics technologies, and also includes a broad discussion of emerging therapies for mitochondrial disease. New insights into both bioenergetic and biosynthetic mitochondrial functionalities have expedited the genetic diagnosis of primary mitochondrial disorders, and identified novel mitochondrial pathomechanisms and new targets for therapeutic intervention. As we enter this new era of mitochondrial medicine, underpinned by global unbiased approaches and multifaceted investigation of mitochondrial function, omics technologies will continue to shed light on unresolved mitochondrial questions, paving the way for improved outcomes for patients with mitochondrial diseases.
引用
- Rahman J, Rahman S. Mitochondrial medicine in the omics era. Lancet. 2018. PMID: 29903433. doi:10.1016/S0140-6736(18)30727-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。